CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 7 enrolled
Drug / intervention
Nicotine Patch +1 moredrug
Likely dose
Nicotine Patch 21 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02918630
NCT02918630N/ACompleted
CompareCT.gov

E-cigarettes to Promote Smoking Reduction Among Individuals With Schizophrenia

The University of Texas Health Science Center, Houston·interventional·Posted Sep 29, 2016·Updated Jul 5, 2018

In Brief

A clinical study evaluating Nicotine Patch and E-cigarette for Tobacco Smoking. Completed, enrolled 7 participants across 1 site.

Detailed Summary

The purpose of this study is to assess if access to an electronic nicotine delivery device, or e-cigarette, in addition to nicotine patch (21 mg) can help reduce cigarette smoking among individuals diagnosed with schizophrenia compared to nicotine patch alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Smoking
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedSep 29, 2016
Enrollment StartOct 1, 2016
Primary CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.8 years ago

Interventions

Nicotine Patchdrug

Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.

E-cigarettedrug

The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).